Episode
Molly Gibson: Superintelligence and the Future of Drug Development
- Podcast
- Behind the Breakthroughs
- Published
- Apr 8, 2026
- Duration seconds
- 3085
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/behind-the-breakthroughs-7055075/episodes/molly-gibson-superintelligence-and-the-future-of-drug-development/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/behind-the-breakthroughs-7055075/molly-gibson-superintelligence-and-the-future-of-drug-development.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
As an Origination Partner at Flagship Pioneering, Molly Gibson, PhD, co-founded her first company, Generate:Biomedicines, in 2018, where she made her mark by developing models that design novel proteins—work that has already led to a Phase 3 asthma drug. Since then, she has gone on to co-found two additional companies: Expedition Medicines and Lila Biosciences. In this episode, Molly explains why the anticipated boom in AI-guided drug development hasn’t fully materialized and how she’s tackling the challenge by modeling complex chemistry to synthesize novel small molecules at Expedition Medicines. She also discusses building "superintelligence" and closed-loop systems in which AI can autonomously generate, test, and refine scientific ideas at Lila Biosciences. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.